author-photo

Jerry Weaver

Celgene

11

Papers

35

Citations

Citation Trend

Filter By

Papers (9) Sort By

Journal Conference Others

Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels

2020 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (1)
Clinical Benefit-Risk Profile of Lenalidomide in Patients With Lower-risk Myelodysplastic Syndromes Without del(5q): Results of a Phase III Trial

2018 Clinical Lymphoma, Myeloma & Leukemia
Show All
- Source
- Cite
- Save
Citations (1)
Azacitidine improves clinical outcomes in older patients with acute myeloid leukaemia with myelodysplasia-related changes compared with conventional care regimens

2017 BMC Cancer
Show All
- Source
- Cite
- Save
Citations (25)
Incidence rates of treatment-emergent adverse events and related hospitalization are reduced with azacitidine compared with conventional care regimens in older patients with acute myeloid leukemia

2017 Leukemia & Lymphoma
Show All
- Source
- Cite
- Save
Citations (4)
Azacitidine Versus Conventional Care Regimens (CCR) in Elderly Patients (≥75 Years) with Acute Myeloid Leukemia (AML) in the AZA-AML-001 Study

2017 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (1)
Azacitidine Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes

2017 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (0)
Effect of Lenalidomide Exposure on Response and Outcomes in Patients with Lower-Risk Non-Del(5Q) Myelodysplastic Syndromes (MDS)

2017 Leukemia Research
Show All
- Source
- Cite
- Save
Citations (0)
Azacitidine (AZA) Prolongs Overall Survival in Older Patients with Acute Myeloid Leukemia (AML) with Poor Prognostic Karyotypes Compared with Conventional Care Regimens (CCR)

2016 Blood
Show All
- Source
- Cite
- Save
Citations (2)
Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)

2016 Blood
Show All
- Source
- Cite
- Save
Citations (1)